Karolinska Development’s portfolio company Umecrine Cognition provides update on ongoing Phase 1b/2a clinical study
Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has provided an update regarding the ongoing clinical phase 1b/2a trial evaluating the ...
Karolinska Development Annual Report 2024 published
Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces publication of its Annual Report 2024. The report is now available to download at For further information, please contact: Viktor ...
Karolinska Development's portfolio company PharmNovo receives positive FDA feedback prior to IND application for Phase 2a trial
Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that portfolio company PharmNovo received positive feedback regarding its most advanced drug candidate, PN6047, in a pre-IND meeting ...
Morningstar11d
Karolinska Development AB Class B
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Taiwan News24d
Karolinska Development’s portfolio company AnaCardio includes first patient in a phase 2a study of its drug candidate AC01
STOCKHOLM, SWEDEN February 25, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has dosed the first patient in the phase 2a part of the ...
Yahoo Finance1mon
Karolinska Developments portfolio company Promimic publishes positive results on reduction of bacteria growth on HAnano Surface
STOCKHOLM, SWEDEN, February 18 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Promimic has published positive results showing a reduction of ...
Karolinska Development AB (publ): Karolinska Development's portfolio company AnaCardio has been granted additional EU patent for drug candidate AC01
Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has been granted patent for its drug candidate AC01 as an inotropic ...
manilatimes4d
Karolinska Development's portfolio company Umecrine Cognition provides update on ongoing Phase 1b/2a clinical study
STOCKHOLM, SWEDEN - March 18, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has provided an update regarding the ongoing ...